These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34811480)

  • 1. High-resolution epitope mapping and characterization of SARS-CoV-2 antibodies in large cohorts of subjects with COVID-19.
    Haynes WA; Kamath K; Bozekowski J; Baum-Jones E; Campbell M; Casanovas-Massana A; Daugherty PS; Dela Cruz CS; Dhal A; Farhadian SF; Fitzgibbons L; Fournier J; Jhatro M; Jordan G; Klein J; Lucas C; Kessler D; Luchsinger LL; Martinez B; Catherine Muenker M; Pischel L; Reifert J; Sawyer JR; Waitz R; Wunder EA; Zhang M; ; Iwasaki A; Ko A; Shon JC
    Commun Biol; 2021 Nov; 4(1):1317. PubMed ID: 34811480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
    Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
    Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope.
    Makdasi E; Levy Y; Alcalay R; Noy-Porat T; Zahavy E; Mechaly A; Epstein E; Peretz E; Cohen H; Bar-On L; Chitlaru T; Cohen O; Glinert I; Achdout H; Israely T; Rosenfeld R; Mazor O
    Viruses; 2021 Mar; 13(4):. PubMed ID: 33810465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs.
    Stoddard CI; Galloway J; Chu HY; Shipley MM; Sung K; Itell HL; Wolf CR; Logue JK; Magedson A; Garrett ME; Crawford KHD; Laserson U; Matsen FA; Overbaugh J
    Cell Rep; 2021 May; 35(8):109164. PubMed ID: 33991511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus.
    Murugavelu P; Perween R; Shrivastava T; Singh V; Ahmad Parray H; Singh S; Chiranjivi AK; Thiruvengadam R; Singh S; Yadav N; Jakhar K; Sonar S; Mani S; Bhattacharyya S; Sharma C; Vishwakarma P; Khatri R; Kumar Panchal A; Das S; Ahmed S; Samal S; Kshetrapal P; Bhatnagar S; Luthra K; Kumar R
    Int Immunopharmacol; 2021 Oct; 99():108020. PubMed ID: 34426117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
    Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
    Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
    Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL
    J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
    Finkelstein MT; Mermelstein AG; Parker Miller E; Seth PC; Stancofski ED; Fera D
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33477902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Analysis of Human and Feline Coronavirus Cross-Reactive Antibodies Directed Against the SARS-CoV-2 Fusion Peptide.
    Vanderheijden N; Stevaert A; Xie J; Ren X; Barbezange C; Noppen S; Desombere I; Verhasselt B; Geldhof P; Vereecke N; Stroobants V; Oh D; Vanhee M; Naesens LMJ; Nauwynck HJ
    Front Immunol; 2021; 12():790415. PubMed ID: 35069571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins.
    Tajuelo A; López-Siles M; Más V; Pérez-Romero P; Aguado JM; Briz V; McConnell MJ; Martín-Galiano AJ; López D
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
    Ishimaru H; Nishimura M; Shigematsu H; Marini MI; Hasegawa N; Takamiya R; Iwata S; Mori Y
    J Virol; 2024 May; 98(5):e0041624. PubMed ID: 38624232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.
    Kramer KJ; Johnson NV; Shiakolas AR; Suryadevara N; Periasamy S; Raju N; Williams JK; Wrapp D; Zost SJ; Walker LM; Wall SC; Holt CM; Hsieh CL; Sutton RE; Paulo A; Nargi RS; Davidson E; Doranz BJ; Crowe JE; Bukreyev A; Carnahan RH; McLellan JS; Georgiev IS
    Cell Rep; 2021 Oct; 37(1):109784. PubMed ID: 34592170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions.
    Shiakolas AR; Kramer KJ; Wrapp D; Richardson SI; Schäfer A; Wall S; Wang N; Janowska K; Pilewski KA; Venkat R; Parks R; Manamela NP; Raju N; Fechter EF; Holt CM; Suryadevara N; Chen RE; Martinez DR; Nargi RS; Sutton RE; Ledgerwood JE; Graham BS; Diamond MS; Haynes BF; Acharya P; Carnahan RH; Crowe JE; Baric RS; Morris L; McLellan JS; Georgiev IS
    Cell Rep Med; 2021 Jun; 2(6):100313. PubMed ID: 34056628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike.
    Guthmiller JJ; Stovicek O; Wang J; Changrob S; Li L; Halfmann P; Zheng NY; Utset H; Stamper CT; Dugan HL; Miller WD; Huang M; Dai YN; Nelson CA; Hall PD; Jansen M; Shanmugarajah K; Donington JS; Krammer F; Fremont DH; Joachimiak A; Kawaoka Y; Tesic V; Madariaga ML; Wilson PC
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.
    Jennewein MF; MacCamy AJ; Akins NR; Feng J; Homad LJ; Hurlburt NK; Seydoux E; Wan YH; Stuart AB; Edara VV; Floyd K; Vanderheiden A; Mascola JR; Doria-Rose N; Wang L; Yang ES; Chu HY; Torres JL; Ozorowski G; Ward AB; Whaley RE; Cohen KW; Pancera M; McElrath MJ; Englund JA; Finzi A; Suthar MS; McGuire AT; Stamatatos L
    Cell Rep; 2021 Jul; 36(2):109353. PubMed ID: 34237283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
    Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
    Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.